Nature Communications (Jul 2021)

A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection

  • Tingting Li,
  • Hongmin Cai,
  • Hebang Yao,
  • Bingjie Zhou,
  • Ning Zhang,
  • Martje Fentener van Vlissingen,
  • Thijs Kuiken,
  • Wenyu Han,
  • Corine H. GeurtsvanKessel,
  • Yuhuan Gong,
  • Yapei Zhao,
  • Quan Shen,
  • Wenming Qin,
  • Xiao-Xu Tian,
  • Chao Peng,
  • Yanling Lai,
  • Yanxing Wang,
  • Cedric A. J. Hutter,
  • Shu-Ming Kuo,
  • Juan Bao,
  • Caixuan Liu,
  • Yifan Wang,
  • Audrey S. Richard,
  • Hervé Raoul,
  • Jiaming Lan,
  • Markus A. Seeger,
  • Yao Cong,
  • Barry Rockx,
  • Gary Wong,
  • Yuhai Bi,
  • Dimitri Lavillette,
  • Dianfan Li

DOI
https://doi.org/10.1038/s41467-021-24905-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Here, the authors report the engineering, structural and biological characterization of synthetic nanobodies (sybodies) that display potent therapeutic activity against SARS-CoV-2 infection in animal models via targeting the virus receptor-binding domain.